|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCNT1 |
Gene summary for CCNT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCNT1 | Gene ID | 904 |
| Gene name | cyclin T1 | |
| Gene Alias | CCNT | |
| Cytomap | 12q13.11-q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | O60563 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 904 | CCNT1 | LZE4T | Human | Esophagus | ESCC | 2.28e-16 | 2.81e-01 | 0.0811 |
| 904 | CCNT1 | LZE7T | Human | Esophagus | ESCC | 6.00e-16 | 6.96e-01 | 0.0667 |
| 904 | CCNT1 | LZE8T | Human | Esophagus | ESCC | 1.83e-07 | 1.29e-01 | 0.067 |
| 904 | CCNT1 | LZE20T | Human | Esophagus | ESCC | 1.97e-03 | 3.87e-02 | 0.0662 |
| 904 | CCNT1 | LZE24T | Human | Esophagus | ESCC | 1.89e-13 | 3.07e-01 | 0.0596 |
| 904 | CCNT1 | P1T-E | Human | Esophagus | ESCC | 2.80e-13 | 3.69e-01 | 0.0875 |
| 904 | CCNT1 | P2T-E | Human | Esophagus | ESCC | 8.19e-39 | 6.20e-01 | 0.1177 |
| 904 | CCNT1 | P4T-E | Human | Esophagus | ESCC | 1.89e-16 | 3.45e-01 | 0.1323 |
| 904 | CCNT1 | P5T-E | Human | Esophagus | ESCC | 4.44e-08 | 1.24e-01 | 0.1327 |
| 904 | CCNT1 | P8T-E | Human | Esophagus | ESCC | 6.61e-23 | 4.56e-01 | 0.0889 |
| 904 | CCNT1 | P9T-E | Human | Esophagus | ESCC | 9.81e-15 | 2.59e-01 | 0.1131 |
| 904 | CCNT1 | P10T-E | Human | Esophagus | ESCC | 1.08e-18 | 3.75e-01 | 0.116 |
| 904 | CCNT1 | P11T-E | Human | Esophagus | ESCC | 3.59e-12 | 4.59e-01 | 0.1426 |
| 904 | CCNT1 | P12T-E | Human | Esophagus | ESCC | 3.92e-15 | 3.36e-01 | 0.1122 |
| 904 | CCNT1 | P15T-E | Human | Esophagus | ESCC | 6.32e-18 | 3.64e-01 | 0.1149 |
| 904 | CCNT1 | P16T-E | Human | Esophagus | ESCC | 1.57e-28 | 5.20e-01 | 0.1153 |
| 904 | CCNT1 | P17T-E | Human | Esophagus | ESCC | 2.23e-03 | 1.59e-01 | 0.1278 |
| 904 | CCNT1 | P20T-E | Human | Esophagus | ESCC | 4.82e-23 | 3.63e-01 | 0.1124 |
| 904 | CCNT1 | P21T-E | Human | Esophagus | ESCC | 1.33e-16 | 2.43e-01 | 0.1617 |
| 904 | CCNT1 | P22T-E | Human | Esophagus | ESCC | 1.05e-24 | 3.98e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
| GO:1903311110 | Esophagus | ESCC | regulation of mRNA metabolic process | 210/8552 | 288/18723 | 3.25e-21 | 5.56e-19 | 210 |
| GO:0050684110 | Esophagus | ESCC | regulation of mRNA processing | 109/8552 | 137/18723 | 3.51e-16 | 2.59e-14 | 109 |
| GO:001908017 | Esophagus | ESCC | viral gene expression | 80/8552 | 94/18723 | 2.04e-15 | 1.28e-13 | 80 |
| GO:000635414 | Esophagus | ESCC | DNA-templated transcription, elongation | 76/8552 | 91/18723 | 8.35e-14 | 4.11e-12 | 76 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:003278412 | Esophagus | ESCC | regulation of DNA-templated transcription, elongation | 45/8552 | 53/18723 | 3.64e-09 | 7.61e-08 | 45 |
| GO:001908312 | Esophagus | ESCC | viral transcription | 41/8552 | 50/18723 | 1.35e-07 | 2.17e-06 | 41 |
| GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
| GO:005068615 | Esophagus | ESCC | negative regulation of mRNA processing | 26/8552 | 29/18723 | 8.98e-07 | 1.15e-05 | 26 |
| GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
| GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
| GO:003144013 | Esophagus | ESCC | regulation of mRNA 3'-end processing | 25/8552 | 28/18723 | 1.77e-06 | 2.10e-05 | 25 |
| GO:00719029 | Esophagus | ESCC | positive regulation of protein serine/threonine kinase activity | 124/8552 | 200/18723 | 2.27e-06 | 2.61e-05 | 124 |
| GO:003278613 | Esophagus | ESCC | positive regulation of DNA-templated transcription, elongation | 24/8552 | 27/18723 | 3.48e-06 | 3.84e-05 | 24 |
| GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
| GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
| GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
| hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
| hsa032502 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
| hsa0325011 | Liver | HCC | Viral life cycle - HIV-1 | 46/4020 | 63/8465 | 3.25e-05 | 1.88e-04 | 1.04e-04 | 46 |
| hsa0325021 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
| hsa0520221 | Prostate | Tumor | Transcriptional misregulation in cancer | 59/1791 | 193/8465 | 1.22e-03 | 5.26e-03 | 3.26e-03 | 59 |
| hsa032503 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
| hsa0520231 | Prostate | Tumor | Transcriptional misregulation in cancer | 59/1791 | 193/8465 | 1.22e-03 | 5.26e-03 | 3.26e-03 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCNT1 | SNV | Missense_Mutation | novel | c.1700N>G | p.Ser567Cys | p.S567C | O60563 | protein_coding | deleterious(0.02) | benign(0.43) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| CCNT1 | SNV | Missense_Mutation | novel | c.355N>T | p.Pro119Ser | p.P119S | O60563 | protein_coding | tolerated(0.84) | benign(0.268) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| CCNT1 | SNV | Missense_Mutation | c.2027N>T | p.Thr676Ile | p.T676I | O60563 | protein_coding | deleterious_low_confidence(0.04) | benign(0.03) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCNT1 | SNV | Missense_Mutation | novel | c.761G>A | p.Arg254His | p.R254H | O60563 | protein_coding | deleterious(0.02) | possibly_damaging(0.824) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCNT1 | SNV | Missense_Mutation | novel | c.929T>C | p.Val310Ala | p.V310A | O60563 | protein_coding | tolerated(0.53) | benign(0.021) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCNT1 | SNV | Missense_Mutation | c.1261N>A | p.Ala421Thr | p.A421T | O60563 | protein_coding | tolerated(0.1) | benign(0.353) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| CCNT1 | SNV | Missense_Mutation | c.2155N>G | p.Pro719Ala | p.P719A | O60563 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| CCNT1 | SNV | Missense_Mutation | novel | c.494N>A | p.Arg165Gln | p.R165Q | O60563 | protein_coding | deleterious(0.04) | benign(0.1) | TCGA-OL-A5RZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
| CCNT1 | SNV | Missense_Mutation | novel | c.203N>A | p.Arg68Gln | p.R68Q | O60563 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCNT1 | SNV | Missense_Mutation | c.935N>G | p.Ser312Cys | p.S312C | O60563 | protein_coding | deleterious(0.03) | benign(0.04) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |